Implantation of a left ventricular assist device in a patient with primary antiphospholipid syndrome.
The antiphospholipid syndrome is characterized by arterial and venous thrombosis and is associated with the presence of circulating antiphospholipid antibodies. Arterial thrombosis can result in myocardial infarction, which may potentially lead to end-stage heart failure. Here we report our anticoagulation protocol for patients with antiphospholipid syndrome that undergo axial-flow left ventricle assist devices (HeartMate II; Thoratec, Pleasanton, CA) implantation.
Meyer
Anna Lassia
AL
Department of Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany.
Kuehn
Christian
C
Gras
Clemens
C
Malehsa
Doris
D
Bara
Christoph
C
Fischer
Stefan
S
Haverich
Axel
A
Strüber
Martin
M
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000925:Anticoagulants / Q000008:administration & dosage; D018951:Antigens, CD20; D016736:Antiphospholipid Syndrome / Q000150:complications* / Q000628:therapy; D006333:Heart Failure / Q000150:complications / Q000628:therapy*; D006353:Heart-Assist Devices; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D010951:Plasma Exchange; D010956:Plasmapheresis; D011300:Preoperative Care; D019919:Prosthesis Implantation / Q000379:methods*; D000069283:Rituximab; D014859:Warfarin / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000925:Anticoagulants; D018951:Antigens, CD20; D000069283:Rituximab; D014859:Warfarin; D006493:Heparin